[The effect of Rosiglitazone, a PPARgamma receptor agonist, on the NF-kappaB signaling pathway in acute hepatic injury induced by LPS].
Li
Li-juan
LJ
Jinci College, Shanxi Medical University, Taiyuan 030025, China. rjnancy2006@163.com
Xu
Rui-ling
RL
D000208:Acute Disease; D000818:Animals; D015153:Blotting, Western; D004195:Disease Models, Animal; D020672:I-kappa B Proteins / Q000378:metabolism; D007274:Injections, Intraperitoneal; D008070:Lipopolysaccharides; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D008107:Liver Diseases / Q000378:metabolism / Q000473:pathology*; D008297:Male; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism*; D052002:NF-kappa B p50 Subunit / Q000378:metabolism; D047495:PPAR gamma / Q000819:agonists*; D011897:Random Allocation; D000077154:Rosiglitazone; D015398:Signal Transduction / Q000187:drug effects*; D045162:Thiazolidinediones / Q000494:pharmacology*
D020672:I-kappa B Proteins; D008070:Lipopolysaccharides; D016328:NF-kappa B; D052002:NF-kappa B p50 Subunit; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone